BRISBANE, Australia – Microba Life Sciences Limited (ASX: MAP) (“Microba” or the “Company”) is pleased to announce that leading medical diagnostics provider Sonic Healthcare Limited (ASX: SHL) (“Sonic”) has agreed to invest $17.8m to acquire a […]
Proge Farm, an Italian pharmaceutical company, has made microbiome history with its recently approved therapeutic and will now be able to market its drug based on Lactobaccilus plantarum P 17630. The company obtained authorization from […]
Holobiome and AsiaBiome announce that they have closed a transaction for the acquisition of AsiaBiome by Holobiome. This acquisition unites two innovative life sciences companies that are committed to finding solutions to promote health through […]
Eligo Bioscience announced the issuance by the US Patent and Trademark Office (USPTO) of the first patent in a wide family covering genetic engineering of a key skin microbiome species, Cutibacterium acnes, to support therapeutic […]
BiomeBank today announced the first regulatory approval for a donor derived microbiome drug product worldwide. The Therapeutic Goods Administration (TGA) approved BiomeBank’s product for restoration of gut microbiota in the treatment of recurrent Clostridioides difficile […]
SYNLAB, the leader in medical diagnostic services and specialty testing in Europe, and Microba Life Sciences (Microba), a global leader in the analysis of complex gut microbiomes, have expanded their strategic agreement to broaden geographic […]
By 2028 the global skin care market is projected to near $145.82 billion1, #skincareproducts2 has two billion plus views and counting on TikTok, and Vogue’s 2022 skin care trends3 include “supporting the skin’s microbiome.” The fascination with skin […]
Lonza, a preferred partner to the pharmaceutical, biotech and nutraceutical markets, has launched an innovative new capsule solution for intestinal (enteric) drug delivery. The Capsugel® Enprotect™ capsule does not disintegrate during stomach transit and only […]